The overlooked hormone driving Alzheimer’s risk in Women

For decades, the conversation around menopause and cognitive decline has centered on estrogen. A growing body of research suggests we may have been looking at the wrong hormone.

Rising FSH during menopause crosses the blood-brain barrier to drive neuroinflammation, metabolic dysfunction, and Alzheimer’s pathology independent of estrogen decline.

By Yasin Ali Muhammad

Every year, about 1.3 million American women go through menopause (Carlson & Vadakekut, 2026). Many will experience something in addition to hot flashes and broken sleep: the slow encroachment of an absent-mindedness, a loss for words in the middle of a sentence, a brain fog that rolls in like weather. Physicians and patients have long suspected this is due to the precipitous drop in estrogen that characterizes the transition. Estrogen is a powerful neuroprotector (Mervosh & Devi, 2025). Lose that, the thinking has been, and the brain will suffer for it.

But a new line of research is muddying that narrative. Scientists are turning their attention to a different hormonal player — one that has been conspicuously absent from the public discourse on menopause and the aging brain: follicle-stimulating hormone, or FSH (Xue et al., 2025). Whereas estrogen declines during the menopause transition, FSH surges and stays elevated. And according to a flurry of new studies, those high levels may not simply be a side effect of ovarian aging. They may be reworking the brain in real time.

Estrogen deficiency may only be part of the story

For years, the logic was simple: as estrogen falls, the brain loses a protective influence, and Alzheimer’s risk goes up. It was a logical, seductive hypothesis, and it guided both clinical care and several decades of research.

But the data hasn’t lined up. Correlational studies of estrogen therapy and cognition have been confoundingly mixed — some reviews have found no effect on Alzheimer’s risk (Melville et al., 2025), and others have suggested that if HRT is started in later-life (as opposed to the “critical window” years around menopause), cognitive outcomes are actually worse (Nerattini et al., 2023). Researchers have wrestled with this problem for years, pointing to nuances in timing and dosing, with little resolution.

A new, peer-reviewed study from Wang et al. (2026), now open access at Frontiers in Aging Neuroscience, suggests it’s not estrogen that matters, but FSH. A team at The Catholic University of Korea measured estradiol and FSH in 884 postmenopausal women across the full spectrum from normal cognition to mild cognitive impairment to Alzheimer’s dementia. They also used amyloid PET imaging, the current gold standard for identifying the protein plaques of Alzheimer’s disease in the living human brain, in a subset of the participants.

FSH was highest in the AD group, intermediate in the MCI group, and lowest in the cognitively normal group, showing a clear, dose-response pattern across disease stages. High FSH also correlated with worse scores on all of the cognitive tests — not just memory, but language, executive function, and visuospatial abilities as well. Women with high amyloid burden on PET scan also had higher FSH than those without. Estradiol, on the other hand, was uncorrelated with any of these outcomes. From stage to stage, from amyloid-positive to amyloid-negative, from memory to language, estradiol levels were flat. Not low estrogen but high FSH was tracking with disease.

Mediation analysis found that the relationship between FSH and cognition appeared to work through amyloid deposition: the higher the FSH, the higher the amyloid, the lower the cognition. But because this was a cross-sectional study, it can’t show if higher FSH comes first, to drive amyloid deposition and cognitive decline; or if the two go up in parallel, pushed by some upstream cause. That’s the central limitation the authors themselves acknowledge in the paper, and what they call for next: longitudinal follow-up.

A cascade, not a single switch

It begins with a signalling cascade you’ve never heard of. The C/EBPβ–δ-secretase/AEP cascade. FSH binding in neurons sets off a domino effect of molecular interactions that culminates in the activation of a protein-snipping enzyme known as delta-secretase. Delta-secretase chops two other proteins, amyloid precursor protein and tau, into smaller pieces that tend to misfold and aggregate. The end result: a direct biochemical pathway from elevated FSH to the characteristic lesions of Alzheimer’s, one that animal experiments have now shown can be blocked by interfering with FSH signalling (Xiong et al., 2022).

That’s just the beginning. The same molecular cascade also disrupts the way neurons uptake and metabolize glucose, in effect creating a kind of insulin resistance inside the neuron (Gabbouj et al., 2019). Neurons that can’t use their primary source of fuel efficiently start to fail silently and gradually, contributing to the patterns of decreased brain metabolism that neuroimaging researchers have long been documenting in women at high Alzheimer’s risk, often long before memory symptoms appear (Cunnane et al., 2011). At the same time, the cascade depletes a key molecule called NAD⁺ that’s required for mitochondrial energy production, compounding the cellular energy crisis (Li et al., 2025).

The disease process may not happen all at once. Early activation of these pathways can, paradoxically, drive neurons into an overactive state — the brain working harder than it should to compensate (Naia et al., 2023). But after a while, that compensation can no longer hold. Mitochondria start to accumulate damage. The cellular machinery that’s normally supposed to clear out misfolded proteins and cellular debris begins to falter (Naia et al., 2023). What starts as an adaptive stress response gradually becomes a self-reinforcing cycle of dysfunction.

Neuroinflammation runs through the whole process. The same molecular switch that FSH flips in neurons also turns on the brain’s immune cells, priming them for a state of chronic, low-grade inflammation (Yao et al., 2024). Inflammation is protective in the short term. It’s destructive when sustained over years, disrupting amyloid clearance, accelerating tau pathology, and gradually degrading the synaptic connections that memory and cognition depend on.

FSH also appears to compromise the blood-brain barrier — the tightly sealed gateway that keeps the harmful substances in the bloodstream from reaching neural tissue. It does this through several converging routes. Elevated FSH triggers the release of inflammatory signals that activate enzymes capable of physically degrading the proteins that hold the barrier’s cellular walls together (Capaldo et al., 2014). It also stimulates the production of molecular “landing pads” on blood vessel walls that recruit white blood cells, which then wedge through the barrier as its structural integrity weakens (Li et al., 2017). And FSH doesn’t merely act from the outside — receptors for it have been detected in the human cortex and hippocampus, and studies suggest FSH can cross the barrier itself to activate the same molecular cascade that drives amyloid and tau pathology deeper in the brain. In animal models, blocking FSH with a neutralizing antibody significantly reduced neuroinflammation and improved the cognitive deficits associated with barrier breakdown (Xiong et al., 2022). This matters because blood-brain barrier disruption is now understood to be one of the earliest detectable events in Alzheimer’s disease — appearing before plaques, before tangles, and before any cognitive complaint (Alkhalifa et al., 2023). If FSH is contributing to that breakdown, it may be shaping the disease long before anyone knows to look for it.

The genetics of risk — and where FSH fits in

APOE4 is the most potent genetic risk factor for late-onset Alzheimer’s disease. Women with one copy have about a two- to three-fold increased risk; women with two copies have a risk that could be tenfold or more (Yamazaki et al., 2019). A large component of that risk is associated with amyloid clearance. APOE4 is a less efficient amyloid scavenger — it forms complexes with amyloid that are cleared poorly by immune cells in the brain and cause more robust inflammation in the process.

The emerging FSH work, then, describes a second, overlapping risk. FSH strongly promotes ApoE production in the ovaries (Driscoll et al., 1985), and that signal translates to increased ApoE levels throughout the body (Von Wald et al., 2010). Brain cells, in turn, also increase ApoE production when they are metabolically (Wynne et al., 2023) or immunologically (Zalocusky et al., 2021) stressed, and as we’ve discussed here, FSH appears to create precisely that kind of stress. The worry is that this additional ApoE, produced under pressure in a compromised metabolic environment, may also be generated in the form that is least functional: ApoE4, poorly equipped to bind and clear amyloid and more likely to promote its accumulation.

That said, and critically, in the Korean cohort I discussed above, the relationship between FSH and amyloid burden persisted in both APOE4 carriers and non-carriers. The FSH-brain pathology link was not simply a by-product of genetic risk. It was independent of it — and that means that FSH may drive neurodegeneration in women without the high-risk gene variant, too. It also means that FSH, APOE4, and amyloid may form a vicious cycle in women with APOE4 risk alleles — a scenario in which FSH and APOE4 provide two mechanisms, with two different mediators, but moving in the same direction, at the same time.

Why women, and why now

Women make up nearly two thirds of all Alzheimer’s cases in the US (Mosconi, 2026). The reason for this disparity has long been chalked up to longevity, but it is increasingly difficult to account for by longevity alone. It’s as though female hormonal history prefigures Alzheimer’s vulnerability in ways that science is only beginning to understand.

The menopause transition has emerged as a plausible window of explanation — not simply because estrogen is lost, but because the entire hormonal architecture of the brain is reorganized. FSH surges. Sleep is disrupted, impairing the brain’s nighttime clearance of metabolic waste. The blood-brain barrier shows early signs of compromise. These processes don’t unfold in isolation; they reinforce each other.

What remains unknown

The FSH hypothesis is tantalizing, but remains just that, a [plausible] hypothesis. The cross-sectional nature of the data, even with its large size and careful statistical adjustments, cannot demonstrate that FSH elevation causes Alzheimer’s pathology — only that the two co-exist. Prospective studies following hormones, brain imaging, and cognitive performance in the same women over time are needed to demonstrate direction of effect, and they don’t yet exist at the scale required.

Even the therapeutic implications are less certain. No FSH-blocking treatment is currently available in a clinical form for human use. Whether suppression of FSH would protect the brain has not yet been tested. And not all women who experience menopause develop Alzheimer’s disease — individual variation, in part due to genetics, lifestyle, and vascular health, is huge.

The conversation that needs to happen

What the emerging science is making abundantly clear, however, is that the hormonal narrative of the aging female brain is far more complicated than the estrogen-centric story that has dominated clinical practice for so long. FSH, in particular, is looking less and less like a bystander, a mere marker of ovarian decline, and more and more like an active player in early Alzheimer’s pathology: with receptors in the brain, downstream effects on the molecular machinery of neurodegeneration, and a measurable, independent relationship to amyloid burden and cognitive decline in human patients.

Women who present with the cognitive symptoms of perimenopause are still overwhelmingly likely to be told the brain fog will lift once the transition is complete. That FSH, produced by their own bodies in extraordinary quantities and sustained at those levels for years, might be leaving a molecular imprint on their neurons is not part of the standard clinical conversation.

It may be time to start having it.

Yasin Ali Muhammad is an interdisciplinary biomedical researcher and published author whose work spans virology, reproductive aging, and neurobiology. He holds a B.S. in Biological Science with a concentration in Molecular Genetics and Cell Biology from Georgia State University.

References

Alkhalifa, A. E., Al-Ghraiybah, N. F., Odum, J., Shunnarah, J. G., Austin, N., & Kaddoumi, A. (2023). Blood-Brain Barrier Breakdown in Alzheimer’s Disease: Mechanisms and Targeted Strategies. International journal of molecular sciences, 24(22), 16288. https://doi.org/10.3390/ijms242216288

Capaldo, C. T., Farkas, A. E., Hilgarth, R. S., Krug, S. M., Wolf, M. F., Benedik, J. K., Fromm, M., Koval, M., Parkos, C., & Nusrat, A. (2014). Proinflammatory cytokine-induced tight junction remodeling through dynamic self-assembly of claudins. Molecular biology of the cell, 25(18), 2710–2719. https://doi.org/10.1091/mbc.E14-02-0773

Carlson K, Vadakekut ES. Menopause. [Updated 2026 Mar 23]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507826/

Cunnane, S., Nugent, S., Roy, M., Courchesne-Loyer, A., Croteau, E., Tremblay, S., Castellano, A., Pifferi, F., Bocti, C., Paquet, N., Begdouri, H., Bentourkia, M., Turcotte, E., Allard, M., Barberger-Gateau, P., Fulop, T., & Rapoport, S. I. (2011). Brain fuel metabolism, aging, and Alzheimer’s disease. Nutrition (Burbank, Los Angeles County, Calif.), 27(1), 3–20. https://doi.org/10.1016/j.nut.2010.07.021

Driscoll, D. M., Schreiber, J. R., Schmit, V. M., & Getz, G. S. (1985). Regulation of apolipoprotein E synthesis in rat ovarian granulosa cells. The Journal of biological chemistry, 260(15), 9031–9038.

Gabbouj, S., Ryhänen, S., Marttinen, M., Wittrahm, R., Takalo, M., Kemppainen, S., Martiskainen, H., Tanila, H., Haapasalo, A., Hiltunen, M., & Natunen, T. (2019). Altered Insulin Signaling in Alzheimer’s Disease Brain — Special Emphasis on PI3K-Akt Pathway. Frontiers in neuroscience, 13, 629. https://doi.org/10.3389/fnins.2019.00629

Li, B., Xie, Z., Wang, M., Nie, S., Qian, Z., Meng, X., Liu, X., Kang, S. S., & Ye, K. (2025). Neuronal C/EBPβ Shortens the Lifespan via Inactivating NAMPT. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 12(21), e2414871. https://doi.org/10.1002/advs.202414871

Li, X., Chen, W., Li, P., Wei, J., Cheng, Y., Liu, P., Yan, Q., Xu, X., Cui, Y., Gu, Z., Simoncini, T., & Fu, X. (2017). Follicular Stimulating Hormone Accelerates Atherogenesis by Increasing Endothelial VCAM-1 Expression. Theranostics, 7(19), 4671–4688. https://doi.org/10.7150/thno.21216

Melville, M., He, L., Desai, R., Nyamayaro, P., Fox, C., Kothari, K. U., Condron, P., Miao, M., Hickey, M., & Spector, A. (2025). Menopause hormone therapy and risk of mild cognitive impairment or dementia: a systematic review and meta-analysis. The lancet. Healthy longevity, 6(12), 100803. https://doi.org/10.1016/j.lanhl.2025.100803

Mervosh, N., & Devi, G. (2025). Estrogen, menopause, and Alzheimer’s disease: understanding the link to cognitive decline in women. Frontiers in molecular biosciences, 12, 1634302. https://doi.org/10.3389/fmolb.2025.1634302=

Mosconi L. (2026). Women’s midlife: the front line of Alzheimer prevention. The Journal of clinical investigation, 136(6), e199832. https://doi.org/10.1172/JCI199832

Naia, L., Shimozawa, M., Bereczki, E., Li, X., Liu, J., Jiang, R., Giraud, R., Leal, N. S., Pinho, C. M., Berger, E., Falk, V. L., Dentoni, G., Ankarcrona, M., & Nilsson, P. (2023). Mitochondrial hypermetabolism precedes impaired autophagy and synaptic disorganization in App knock-in Alzheimer mouse models. Molecular psychiatry, 28(9), 3966–3981. https://doi.org/10.1038/s41380-023-02289-4

Nerattini, M., Jett, S., Andy, C., Carlton, C., Zarate, C., Boneu, C., Battista, M., Pahlajani, S., Loeb-Zeitlin, S., Havryulik, Y., Williams, S., Christos, P., Fink, M., Brinton, R. D., & Mosconi, L. (2023). Systematic review and meta-analysis of the effects of menopause hormone therapy on risk of Alzheimer’s disease and dementia. Frontiers in aging neuroscience, 15, 1260427. https://doi.org/10.3389/fnagi.2023.1260427

Von Wald, T., Monisova, Y., Hacker, M. R., Yoo, S. W., Penzias, A. S., Reindollar, R. R., & Usheva, A. (2010). Age-related variations in follicular apolipoproteins may influence human oocyte maturation and fertility potential. Fertility and sterility, 93(7), 2354–2361. https://doi.org/10.1016/j.fertnstert.2008.12.129

Wang, S. M., Jeong, C., Um, Y. H., Kang, D. W., Kim, S., Lee, S., Lee, C. U., Aizenstein, H. J., Baek, K. H., & Lim, H. K. (2026). Follicle-stimulating hormone linked to cognitive decline and amyloid burden in postmenopausal women. Frontiers in aging neuroscience, 17, 1697255. https://doi.org/10.3389/fnagi.2025.1697255

Wynne, M. E., Ogunbona, O., Lane, A. R., Gokhale, A., Zlatic, S. A., Xu, C., Wen, Z., Duong, D. M., Rayaprolu, S., Ivanova, A., Ortlund, E. A., Dammer, E. B., Seyfried, N. T., Roberts, B. R., Crocker, A., Shanbhag, V., Petris, M., Senoo, N., Kandasamy, S., Claypool, S. M., … Faundez, V. (2023). APOE expression and secretion are modulated by mitochondrial dysfunction. eLife, 12, e85779. https://doi.org/10.7554/eLife.85779

Xiong, J., Kang, S. S., Wang, Z., Liu, X., Kuo, T. C., Korkmaz, F., Padilla, A., Miyashita, S., Chan, P., Zhang, Z., Katsel, P., Burgess, J., Gumerova, A., Ievleva, K., Sant, D., Yu, S. P., Muradova, V., Frolinger, T., Lizneva, D., Iqbal, J., … Ye, K. (2022). FSH blockade improves cognition in mice with Alzheimer’s disease. Nature, 603(7901), 470–476. https://doi.org/10.1038/s41586-022-04463-0

Xue, Y., Zuo, S., Wang, F., & Qi, X. (2025). From hormones to neurodegeneration: how FSH drives Alzheimer’s disease. Frontiers in aging neuroscience, 17, 1578439. https://doi.org/10.3389/fnagi.2025.1578439

Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C. C., & Bu, G. (2019). Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nature reviews. Neurology, 15(9), 501–518. https://doi.org/10.1038/s41582-019-0228-7

Yao, Q., Long, C., Yi, P., Zhang, G., Wan, W., Rao, X., Ying, J., Liang, W., & Hua, F. (2024). C/EBPβ: A transcription factor associated with the irreversible progression of Alzheimer’s disease. CNS neuroscience & therapeutics, 30(4), e14721. https://doi.org/10.1111/cns.14721

Zalocusky, K. A., Najm, R., Taubes, A. L., Hao, Y., Yoon, S. Y., Koutsodendris, N., Nelson, M. R., Rao, A., Bennett, D. A., Bant, J., Amornkul, D. J., Xu, Q., An, A., Cisne-Thomson, O., & Huang, Y. (2021). Neuronal ApoE upregulates MHC-I expression to drive selective neurodegeneration in Alzheimer’s disease. Nature neuroscience, 24(6), 786–798. https://doi.org/10.1038/s41593-021-00851-3